J&J Commits $1B for Pennsylvania Cell Therapy Plant

The new facility will employ over 500 people and produce cell therapies for thousands of patients annually.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Johnson & Johnson has announced plans to invest over $1 billion to build a new cell therapy manufacturing facility in Montgomery County, Pennsylvania. The plant, expected to be operational by 2031, will employ 500 people and produce cell therapies for thousands of patients each year. J&J cited Pennsylvania's talent pool and academic institutions as key factors in selecting the location.

Why it matters

This investment highlights the growing demand for cell and gene therapies, which are a rapidly expanding area of pharmaceutical research and development. The new J&J facility will help increase production capacity for these personalized treatments, which can be critical for patients with limited treatment options.

The details

J&J's new cell therapy plant will be located in Montgomery County, Pennsylvania. Construction is set to begin in the second half of 2026, with the facility expected to start producing cell therapies for patients in 2031. The plant will employ over 500 people once fully operational. J&J cited Pennsylvania's talent pool and academic institutions as key factors in selecting the location, and the state is providing up to $2.5 million to a local community college or technical school to help train the workforce.

  • J&J plans to start construction on the new facility in the second half of 2026.
  • The plant is expected to begin producing cell therapies for patients in 2031.

The players

Johnson & Johnson

A multinational pharmaceutical and medical devices company.

Joaquin Duato

CEO of Johnson & Johnson.

Pennsylvania

The state where J&J is building its new cell therapy manufacturing facility.

Got photos? Submit your photos here. ›

What they’re saying

“When fully operational, the new site will serve thousands of patients each year, shortening delivery times for these very personalized therapies.”

— Joaquin Duato, CEO, Johnson & Johnson (biospace.com)

What’s next

J&J plans to begin hiring some of the 500 employees 'much earlier' so they can perform validation work at the plant before it becomes fully operational.

The takeaway

This investment by J&J underscores the growing importance of cell and gene therapies in the pharmaceutical industry. The new facility in Pennsylvania will help increase production capacity for these personalized treatments, which can be life-changing for patients with limited options.